Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 11:42 AM ET

Pharmaceuticals

Company Overview of RuiYi Inc.

Company Overview

RuiYi Inc. engages in the discovery and development of novel biologic therapeutics that meet medical and commercial needs for China's patients and healthcare system. It provides monoclonal antibodies that target G protein coupled receptors for therapeutic needs globally. The company was incorporated in 2006 and is based in La Jolla, California with a research facility in Shanghai, China.

505 Coast Boulevard

Suite 300

La Jolla, CA 92037

United States

Founded in 2006

Phone:

858-587-4815

Fax:

858-587-4854

Key Executives for RuiYi Inc.

Chief Executive Officer, President and Director
Chief Financial Officer
Age: 44
Senior Vice President of Research & Development, Bology & Pharmacology
Vice President of Business Development
Vice President of Translational Research
Compensation as of Fiscal Year 2014.

RuiYi Inc. Key Developments

RuiYi Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 03:00 PM

RuiYi Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 03:00 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.

RuiYi Inc. Appoints Mark Saad as Chief Financial Officer

RuiYi Inc. announced the appointment of Mark Saad as chief financial officer (CFO). Mr. Saad was most recently CFO at Cytori Therapeutics for the past ten years. At RuiYi, he will play a critical leadership role in executing the company's growth strategy for important global therapeutic needs. Prior to Cytori, Mr. Saad served as executive director in the Investment Banking Department at UBS.

RuiYi Signs Research Collaboration with iHuman Institute at ShanghaiTech University

RuiYi has signed a new research collaboration with iHuman Institute at ShanghaiTech University. The contract is for applying RuiYi's iCAPS (Intermembranous Antigen Presenting System) technology to develop new monoclonal antibodies with specific binding to G protein coupled receptors, in order to investigate the biological function and structure of G protein coupled receptors.

Similar Private Companies By Industry

Company Name Region
BML Pharmaceuticals, Inc. United States
Aprecia Pharmaceuticals Company United States
LBB Industries, Inc. United States
SICOR, Inc. United States
Marathon Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RuiYi Inc., please visit www.ruiyibio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.